Information Provided By: 
Fly News Breaks for April 30, 2015
AMGN, ALDR
Apr 30, 2015 | 07:50 EDT
Leerink raised its price target for Alder Biopharmaceuticals (ALDR) to $40 saying the abstract for Amgen's (AMGN) AMG334 at the International Headache Society lifts an overhang as it shows that the profile for the company's ALD403 continues to look best-in-class. The firm also expects Phase 2b data in Q4 for ALD403 IV in chronic migraine to boost shares of Alder. Leerink reiterates an Outperform rating on the name.
News For ALDR;AMGN From the Last 2 Days
There are no results for your query ALDR;AMGN
